Skip to main content

Advertisement

Log in

Infographic: intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration (VIEW 1 and VIEW 2)

  • Image
  • Published:
Eye Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: The VIEW 1 and VIEW 2 are similarly designed, phase 3 studies which sought to compare monthly and every-2-monthly aflibercept versus monthly ranibizumab intravitreal injections for neovascular age-related macular degeneration (AMD) [1].

Reference

  1. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.

Download references

Author information

Authors and Affiliations

Authors

Contributions

All authors (KGRC, JKPCD, DMMM, and JCMA) equally contributed to the conceptualization and creation of the visual abstract.

Corresponding author

Correspondence to Jose Carlo M. Artiaga.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crisostomo, K.G.R., Dantes, J.K.P.C., Magpantay, D.M.M. et al. Infographic: intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration (VIEW 1 and VIEW 2). Eye (2023). https://doi.org/10.1038/s41433-023-02835-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41433-023-02835-y

  • Springer Nature Limited

Navigation